This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

LifeSci Advisors Announces Investment Opinion On Genta Incorporated

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Genta Incorporated (OTCBB: GNTA.OB), a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.

“Genta is currently advancing tesetaxel, the leading oral taxane in clinical development, in multiple cancer indications. A Phase III trial design for tesetaxel has been submitted to FDA for a Special Protocol Assessment (SPA) in advanced gastric cancer, where tesetaxel has already demonstrated strong anti-cancer activity and there is a significant unmet medical need,” commented Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “In addition to tesetaxel, many investors associate Genta with Genasense®, whose prospects in the ongoing AGENDA Phase III melanoma trial have been largely discounted following disappointing interim results, but Genasense® still represents a significant opportunity. A detailed analysis of data and statistics for Genasense® in the report support our cautious optimism that the drug might still hit the important overall survival (OS) endpoint despite missing on Progression Free Survival (PFS). The current situation with Genasense® is analogous to the recent Provenge® story with Dendreon in prostate cancer, and Bristol-Myers Squibb’s ipilimumab in melanoma, both of which also recently hit on OS after missing on PFS.”

LifeSci Advisors’ 63-page Initiation Report discusses in depth Genta’s lead drug candidates in development. These include: tesetaxel, a novel, orally absorbed taxane in the same drug class as paclitaxel and docetaxel; Genasense® (oblimersen sodium injection), which is a modified DNA-based antisense Bcl-2 inhibitor drug that may enhance the effectiveness of anticancer therapy; and oral gallium, which is being evaluated as potential treatment for diseases associated with accelerated bone loss. Tesetaxel has shown activity against multiple tumor types during the 5 Phase II studies that have been completed, with additional Phase II studies ongoing or planned. The company has announced their intention to pursue advanced gastric cancer as the lead indication for tesetaxel, and is working to finalize a Phase III study design for tesetaxel in that indication based on guidance from regulatory agencies in the US and Europe. Final overall survival data is expected from Genta’s Phase III AGENDA trial for Genasense® in 1H2011. In addition, Genta is developing an oral formulation of their marketed product Ganite® (gallium nitrate injection), which is marketed in the U.S. and is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The oral gallium products, with their improved convenience and pharmacokinetics, have potential to treat several bone loss indications with large unmet needs, including bone metastases, Paget’s disease and osteoporosis. Further included in the report is a complete background of Genta’s clinical programs, their clinical performances to date, competitive landscapes, upcoming expected milestones, market dynamics upon approval, and associated risks.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs